NASDAQ : BIVI
BioVie Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.43 USD (Oct 30, 2026, 3:25 PM EDT) · Market cap 10.79M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 10.48M |
| Enterprise Value | 1.78M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 7.54M |
| Shares Outstanding | 7.54M |
| Shares Change (YoY) | +390.46% |
| Shares Change (QoQ) | +5.05% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 28.96% |
| Float | 7.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.59 |
| Quick Ratio | 2.93 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,265.39 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -150.76% |
| Return on Assets (ROA) | -79.06% |
| Return on Invested Capital (ROIC) | -94.67% |
| Return on Capital Employed (ROCE) | -216.67% |
| Weighted Average Cost of Capital (WACC) | 8.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.70M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -21.43% |
| 50-Day Moving Average | 1.63 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 48.12 |
| Average Volume (20 Days) | 168,377 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 544,444 |
| Short Previous Month | 831,296 |
| Short % of Shares Out | 7.22% |
| Short % of Float | 7.28% |
| Short Ratio (days to cover) | 1.87 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.65M |
| Pretax Income | -22.07M |
| Net Income | -22.12M |
| EBITDA | -22.47M |
| EBIT | -22.65M |
| Earnings Per Share (EPS) | -$3.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 8.98M |
| Total Debt | 275,430 |
| Net Cash | 8.70M |
| Net Cash Per Share | $1.15 |
| Equity (Book Value) | 10.27M |
| Book Value Per Share | 1.36 |
| Working Capital | 9.85M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -19.02M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 178,341 |
| Net Borrowing | n/a |
| Free Cash Flow | -19.02M |
| FCF Per Share | -$2.52 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -390.46% |
| Shareholder Yield | -390.46% |
| Earnings Yield | -219.70% |
| FCF Yield | -176.38% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.26 |
| Price Target Difference | 278.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |